№ files_lp_3_process_7_105338
File format: docx
Character count: 12980
File size: 589 KB
Year:
2023
Region / City:
Not specified
Document type:
Medical Case Report
Organization / Institution:
Not specified
Author:
Nicole Wiebe, Liena Zhao, Jessica P. Woolfson
Target audience:
Healthcare professionals, pediatric gastroenterologists
Period of action:
Not specified
Date of approval:
Not specified
Date of changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Published date:
Saturday 14 September 2013
Last reviewed:
Thursday 28 July 2022
Type of document:
Clinical audit protocol
Clinical domain:
Thoracic radiology
Subject:
Follow-up of indeterminate pulmonary nodules on CT
Guidelines referenced:
British Thoracic Society guidelines; Fleischner Society guidelines; Royal College of Radiologists iRefer
Target population:
Adults over 18 years with pulmonary nodules detected on CXR or CT
Standard:
Follow-up of indeterminate pulmonary nodules in accordance with BTS and RCR guidelines
Audit targets:
95% compliance in reporting recommendations and follow-up timing
Methodology:
Retrospective audit of CT reports and follow-up imaging using PACS/RIS
Suggested sample size:
50–75 CT examinations
Author:
Denis Remedios
Contributing sources:
Fleischner Society; British Thoracic Society; Royal College of Radiologists
Year:
2015
Region / City:
Rewa, MP
Topic:
Diagnosis of thyroid nodules
Document Type:
Original Article
Organization / Institution:
Shyam Shah Medical College and Sanjay Gandhi Memorial Hospital
Authors:
Qureishi R, Usmani M H, Singh U R, Kol P C, Valame S
Target Audience:
Medical professionals, researchers in pathology and endocrinology
Period of Validity:
Not specified
Date of Approval:
Not specified
Date of Changes:
Not specified
Note:
Year
Topic:
Unusual Incident Reporting
Document Type:
Incident Report
Authority / Institution:
Department of Aging
Target Audience:
Facility Staff, Licensing Agencies
Year:
2023
Region / City:
N/A
Topic:
Weight loss, fat reduction, blood sugar control
Document Type:
Email marketing content
Author:
N/A
Target Audience:
Health-conscious individuals, weight loss seekers
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2023
Region / city:
Pittsburgh, PA, U.S.A.
Topic:
Hematology, Oncology, Dermatology
Document type:
Case Report
Institution:
Allegheny General Hospital
Author:
Muhammad Ali Butt, Sameen Aamer, Anastasios Kapetanos
Target audience:
Healthcare professionals, researchers in hematology and oncology
Date of approval:
Not specified
Date of changes:
Not specified
Keywords:
Henoch-Schonlein Purpura, acute myeloid leukemia, cutaneous presentation of acute myeloid leukemia
Abstract:
This document reports an unusual case of Henoch-Schonlein Purpura (HSP) as the presenting symptom of Acute Myeloid Leukemia (AML).
Contextual description:
A case report of a patient who presented with a rash consistent with Henoch-Schonlein Purpura, later diagnosed with Acute Myeloid Leukemia.
Year:
2026
Region / City:
Merrysville area
Theme:
Strange local events and unusual animal and vehicle behavior
Document Type:
Narrative account
Author:
Loid, student at Twinkle Elementary
Target Audience:
General readership
Period Covered:
Recent days leading up to the account
Location Details:
Area surrounding Merrysville, including nearby town Podunk
Key Events:
Animal attacks, autonomous vehicle movement, rockslide blocking access, unusual phenomena near Mt. Itoi
Primary Subjects:
Loid, Ninten, local children and adults
Observation Points:
School rooftop, local roads and landscape
Year:
Not specified
Region / City:
Not specified
Topic:
Infliximab dose escalation in Crohn’s disease treatment
Document type:
Medical request letter
Institution / Organization:
Not specified
Author:
Not specified
Target audience:
Insurance company
Period of validity:
Not specified
Approval date:
Not specified
Date of modifications:
Not specified
Year:
[Insert Year]
Region / City:
[Insert City, State ZIP]
Topic:
Medical treatment authorization
Document type:
Request letter
Organization / Institution:
[Insert Organization Name]
Target audience:
Medical Director, Payer (Insurance Company)
Period of validity:
[Insert Start Date] - [Insert End Date]
Approval date:
[Insert Date of Approval]
Amendment date:
[Insert Date of Changes if any]
Year:
2026
Region / city:
Multiple centers
Topic:
Medical research, Crohn’s disease
Document type:
Research study
Organization / institution:
Various medical institutions
Author:
Not specified
Target audience:
Medical professionals, researchers
Period of validity:
N/A
Approval date:
N/A
Modification date:
N/A
Year:
2024
Region / city:
Tangier, Morocco
Topic:
Inflammatory Bowel Disease, Crohn’s Disease
Document Type:
Research Study
Organization / Institution:
Mohamed VI University Hospital, Hepato-Gastroenterology Department
Authors:
K. Attaqi, F.Z. Bouamama, S. Temsamani, A. Akjay, H. Ouaya, H. Meyiz, I. Mellouki
Target Audience:
Medical professionals, gastroenterologists
Period of Action:
2020-2024
Approval Date:
N/A
Date of Changes:
N/A
Year:
2022
Country:
United States
Study name:
Study of a Prospective Adult Research Cohort with IBD (SPARC IBD)
Affiliated organization:
Crohn’s & Colitis Foundation
Study type:
Prospective cohort study
Number of centers:
17
Population:
Adult patients with Crohn’s disease initiating vedolizumab or ustekinumab after anti-TNF therapy
Exposures:
Ustekinumab, Vedolizumab, Anti-TNF inhibitors
Outcomes:
Treatment discontinuation, Crohn’s disease–related surgery, malignancy, cardiac events, thromboembolic events
Data sources:
Commercial claims data, SPARC IBD cohort data
Coding systems:
ICD-10-CM, ICD-10-PCS, HCPCS Level I and II, CPT-4, NDC
Sample size (SPARC IBD subset):
Vedolizumab n=77; Ustekinumab n=227
Primary measures:
Incidence rates per 1000 person-years, hazard ratios with 95% confidence intervals
Citation:
Raffals LE, Saha S, Bewtra M, et al. Inflamm Bowel Dis 2022;28:192–199
Year:
2026
Study Type:
Clinical trial
Phase:
Phase 2
Intervention:
Tesnatilimab, Ustekinumab, Placebo
Primary Endpoint:
Change from baseline in CDAI score at Weeks 8 and 12
Secondary Endpoints:
Clinical remission, clinical response, PRO-2 score, SES-CD, GHAS
Analysis Methods:
ANCOVA, MMRM, Cochran-Mantel-Haenszel chi-square test, Multiple Comparison Procedures
Sample Size:
60 patients per arm (Week 8), 50 patients per arm (Week 12)
Power:
84% (Week 8), 85% (Week 12)
Error Rate:
0.05 (two-sided)
Covariates:
Baseline CDAI score, SNP-positive status, Bio-IR status, study visit, visit-by-treatment interaction
Year:
2017
Region:
International (studies from Europe, Australasia, North America)
Topic:
Paediatric Crohn’s disease, nutrition therapy
Document type:
Review article
Institution:
Southampton Children’s Hospital, University of Southampton
Authors:
James J Ashton, Joan Gavin, R Mark Beattie
Keywords:
Crohn’s disease, nutrition, paediatric, exclusive enteral nutrition
Population:
Children and selected adult patients with Crohn’s disease
Study period:
1980–2017
Evidence sources:
Randomised controlled trials, observational studies, retrospective studies, meta-analyses, review articles, editorials, conference abstracts, case reports
Main focus:
Induction of remission, immune modulation, microbiome changes, growth and nutritional outcomes
Guideline references:
ECCO, ESPGHAN, NASPGHAN, ESPEN